Tags : Agitation

BioXcel Reports the US FDA’s Acceptance of BXCL501’s NDA for

Tuba Khan May 19, 2021

Shots: The NDA submission is based on P-III studies (SERENITY I & II) assessing BXCL501 (120 & 180mcg doses) vs PBO for the acute treatment of agitation associated with schizophrenia […]readmore

Regulatory

BioXcel’s BXCL501 Receives the US FDA’s Breakthrough Therapy Designation for

Tuba Khan March 15, 2021

Shots: The BTD is based on a P-Ib/II TRANQUILITY study assessing BXCL501 in patients with acute treatment of agitation associated with dementia, including AD The results demonstrated significant reductions in […]readmore

Tags : Agitation

BioXcel Reports the US FDA’s Acceptance of BXCL501’s NDA for

BioXcel’s BXCL501 Receives the US FDA’s Breakthrough Therapy Designation for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Agitation

BioXcel Reports the US FDA’s Acceptance of BXCL501’s NDA for

BioXcel’s BXCL501 Receives the US FDA’s Breakthrough Therapy Designation for

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company